Not applicableWithdrawnNCT03492268What this trial is testingSafety and Efficacy Evaluation of BCMA-CART for Treating Multiple MyelomaWho this might be right forMultiple Myeloma Bioray Laboratories
Testing effectiveness (Phase 2)Ended earlyNCT00567229What this trial is testingLenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Memorial Sloan Kettering Cancer Center 3
Early research (Phase 1)Study completedNCT01432353What this trial is testingDFRF4539A in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Genentech, Inc. 39
Very early researchUnknownNCT04412889What this trial is testingBCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MMWho this might be right forMultiple Myeloma Hebei Yanda Ludaopei Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT06232096What this trial is testingMBS314 in Participants With Relapsed/Refractory Multiple Myeloma.Who this might be right forRelapsed or Refractory Multiple Myeloma Beijing Mabworks Biotech Co., Ltd. 154
Testing effectiveness (Phase 2)Study completedNCT00558675What this trial is testingA Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological MalignancyWho this might be right forHematological MalignancyLeukemiaLymphoma+1 more Mirror Biologics, Inc. 6
Testing effectiveness (Phase 2)Study completedNCT01955434What this trial is testingSMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma Mayo Clinic 25
Testing effectiveness (Phase 2)WithdrawnNCT00085345What this trial is testingMelphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forStage II Multiple MyelomaStage III Multiple MyelomaRefractory Plasma Cell Neoplasm Oncotherapeutics
Not applicableStudy completedNCT00005799What this trial is testingFludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+42 more Fred Hutchinson Cancer Center 55
Very early researchUnknownNCT04182581What this trial is testingBCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Xijing Hospital 18
Early research (Phase 1)Study completedNCT03338972What this trial is testingImmunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple MyelomaWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma Fred Hutchinson Cancer Center 28
Early research (Phase 1)Looking for participantsNCT07255898What this trial is testingBL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic MalignanciesWho this might be right forMultiple MyelomaHematologic Malignancies Sichuan Baili Pharmaceutical Co., Ltd. 33
Early research (Phase 1)Looking for participantsNCT05650632What this trial is testingAssess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma AbbVie 210
Testing effectiveness (Phase 2)WithdrawnNCT03701321What this trial is testingDaratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06292780What this trial is testingA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)Who this might be right forRelapsed/Refractory Systemic Light Chain Amyloidosis Regeneron Pharmaceuticals 220
Testing effectiveness (Phase 2)Ended earlyNCT00352742What this trial is testingATN-224 and Bortezomib in Patients With Multiple MyelomaWho this might be right forMultiple Myeloma Attenuon 46
Testing effectiveness (Phase 2)UnknownNCT03312205What this trial is testingCAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid MalignanciesWho this might be right forLeukemiaLymphomaMultiple Myeloma of Bone (Diagnosis) Hebei Senlang Biotechnology Inc., Ltd. 50
Testing effectiveness (Phase 2)Study completedNCT00814541What this trial is testingPAD. ICORG 05-01, V11Who this might be right forMultiple Myeloma and Plasma Cell Neoplasm Cancer Trials Ireland 53
Large-scale testing (Phase 3)Study completedNCT03859427What this trial is testingA Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Amgen 454
Not applicableLooking for participantsNCT06961669What this trial is testingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell LymphomaWho this might be right forLymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM) Anhui Provincial Hospital 18